Latest Therapeutics News

Page 8 of 90
Arovella Therapeutics has released the first clinical batch of its off-the-shelf cell therapy ALA-101 and activated its inaugural trial site at The Alfred, setting the stage for patient dosing later this month.
Ada Torres
Ada Torres
7 Sept 2026
Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.
Ada Torres
Ada Torres
4 Sept 2026
Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.
Ada Torres
Ada Torres
2 Sept 2026
Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.
Ada Torres
Ada Torres
1 Sept 2026
Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.
Ada Torres
Ada Torres
1 Sept 2026
Ramsay Health Care has finalised its $251 million purchase of National Capital Private Hospital in Canberra, expanding its footprint in key therapeutic areas and expecting earnings accretion within a year.
Ada Torres
Ada Torres
1 Sept 2026
Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.
Ada Torres
Ada Torres
31 Aug 2026
Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.
Ada Torres
Ada Torres
31 Aug 2026
Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.
Ada Torres
Ada Torres
31 Aug 2026
Salter Brothers Emerging Companies Limited (ASX:SB2) swung to a $7.9 million loss for FY26, driven by a $10.5 million investment write-down, while maintaining dividend payments and extending its share buy-back program.
Claire Turing
Claire Turing
31 Aug 2026
Alterity Therapeutics has arranged an underwriting deal for up to 8.4 million ATHO options, potentially raising A$4.2 million to A$7.96 million ahead of their expiry. The funds aim to support the upcoming Phase 3 trial for ATH434 in Multiple System Atrophy and bolster working capital.
Ada Torres
Ada Torres
31 Aug 2026
Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.
Ada Torres
Ada Torres
31 Aug 2026

Browse the archive

Full archive